Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Tiziana Life Sciences ( (TLSA) ) is now available.
On February 11, 2025, Tiziana Life Sciences announced that its investigational drug, intranasal foralumab, was featured in a news segment highlighting its potential for treating moderate Alzheimer’s disease. The segment included the experiences of the first patient dosed in the expanded access program, emphasizing the hope foralumab offers in addressing neurodegenerative diseases. This drug aims to modulate the immune system to reduce inflammation, a key factor in Alzheimer’s disease, and has shown promise in dampening microglial activation, a critical component of several neurodegenerative diseases.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. Their lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody, currently in clinical development, offering an alternative to intravenous delivery with potential improvements in efficacy, safety, and tolerability.
YTD Price Performance: 1.47%
Average Trading Volume: 623,585
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $75.25M
For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.
